.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Charles J. Ryan, MD

Articles

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

November 1st 2017

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Dr. Charles Ryan on Impact of IMAAGEN Trial in Nonmetastatic CRPC

July 15th 2016

Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

June 23rd 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Dr. Charles Ryan on Abiraterone in mCRPC

March 9th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Ryan on the Long Term Safety of Abiraterone Use

February 27th 2015

Dr. Charles Ryan on Prescribing Preferences

March 13th 2014

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Dr. Ryan on the Unblinding of the COU-AA-302 Trial

August 13th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial

Dr. Ryan on Neoadjuvant Abiraterone Acetate

July 11th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Dr. Ryan Discusses Sequencing Prostate Cancer Therapies

June 18th 2012

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Dr. Ryan on the COU-AA-302 Interim Analysis Results

June 11th 2012

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.